Kennedy's antidepressant initiative: Experts weigh in

Health and Human Services Secretary Robert F. Kennedy Jr. announced a federal initiative in May 2026 aimed at reducing the overuse of psychiatric medications, particularly selective serotonin reuptake inhibitors (SSRIs) such as Prozac, Zoloft, Lexapro, and Paxil. The plan was introduced during a Make America Healthy Again Institute mental health summit and is supported by a joint directive from the Substance Abuse and Mental Health Services Administration, Centers for Medicare & Medicaid Services, Health Resources and Services Administration, and the Administration for Children and Families. The directive acknowledges the value of psychiatric medications, stating they can reduce symptoms, improve functioning, and support recovery, while emphasizing that deprescribing should be a deliberate, individualized process rather than a blanket reduction. The initiative outlines three key strategies: expanding provider training, developing updated clinical guidelines, and modifying insurance reimbursement policies through CMS. Federal agencies will also publish prescribing trend data and promote access to evidence-based alternatives, including psychotherapy and family support services. Special attention is given to vulnerable groups such as children, adolescents, older adults, pregnant or postpartum individuals, and patients on multiple psychiatric medications, with foster youth identified as particularly at risk for overprescribing. Dr. Benjamin Cocchiaro, Assistant Professor of Community Health and Prevention at the Dornsife School of Public Health, noted the directive highlights valid concerns about the role of psychotherapy and physical activity in treating depression, citing meta-analyses showing these interventions can be as effective as SSRIs. However, Cocchiaro raised concerns about the initiative’s broader intentions, questioning whether it will limit patient access and treatment choices rather than improve care. He emphasized the importance of informed decision-making in primary care and warned that constricted options could hinder patient outcomes. Kennedy’s broader stance on psychiatric medications has sparked controversy, with claims that antidepressants are overprescribed and contribute to dependency, violence, and fetal health risks. His statements, including comparisons of antidepressant withdrawal to heroin withdrawal, contrast sharply with the measured language in the federal directive. Critics argue that his rhetoric could undermine public trust in evidence-based treatments while the directive itself seeks to balance caution with access to care. The directive’s focus on expanding training and clinical guidance aims to ensure safer prescribing practices, particularly for high-risk populations. However, experts remain divided over whether the initiative will effectively address overprescribing without unintended consequences for patients who rely on these medications for symptom management and recovery.